NASDAQ: CELUCelularity Inc Stock
$2.33+0.16 (+7.37%)
Updated May 20, 2025
CELU Price
$2.33
Fair Value Price
N/A
Market Cap
$55.80M
52 Week Low
$1.00
52 Week High
$5.22
P/E
-0.88x
P/B
6.31x
P/S
0.84x
PEG
N/A
Dividend Yield
N/A
Revenue
$54.22M
Earnings
-$57.89M
Gross Margin
72.4%
Operating Margin
-95.22%
Profit Margin
-106.8%
Debt to Equity
14.01
Operating Cash Flow
-$6M
Beta
1.06
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CELU Overview
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy. It also sells and licenses products that are used in surgical and wound care markets, such as Biovance and Interfyl; collects stem cells from umbilical cords and placentas; and provides cells storage under the LifebankUSA brand. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CELU's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CELU
Ranked#294 of 454
Ranked#294 of 454
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $47.20 | A | |
| $8.30 | A | |
| $65.30 | A |
Be the first to know about important CELU news, forecast changes, insider trades & much more!
CELU News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CELU scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CELU is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CELU is poor value based on its book value relative to its share price (6.31x), compared to the US Biotechnology industry average (4.37x)
P/B vs Industry Valuation
CELU is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more CELU due diligence checks available for Premium users.
Valuation
CELU price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.88x
Industry
-156.07x
Market
25.56x
CELU price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
6.31x
Industry
4.37x
CELU is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CELU's financial health
Profit margin
Revenue
$18.1M
Net Income
-$13.3M
Profit Margin
-73.3%
CELU's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
CELU's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$132.7M
Liabilities
$123.8M
Debt to equity
14.01
CELU's short-term liabilities ($53.68M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CELU's long-term liabilities ($70.17M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CELU's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CELU's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$1.6M
Investing
-$1.6M
Financing
$643.0k
CELU's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CELU vs Biotech Stocks
Celularity Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.